keyword
MENU ▼
Read by QxMD icon Read
search

Breast diseases

keyword
https://www.readbyqxmd.com/read/29667444/akt2-sirna-delivery-with-amphiphilic-based-polymeric-micelles-show-efficacy-against-cancer-stem-cells
#1
Diana Rafael, Petra Gener, Fernanda Andrade, Joaquin Seras-Franzoso, Sara Montero, Yolanda Fernández, Manuel Hidalgo, Diego Arango, Joan Sayós, Helena F Florindo, Ibane Abasolo, Simó Schwartz, Mafalda Videira
Development of RNA interference-based therapies with appropriate therapeutic window remains a challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. A new amphihilic-based gene delivery system that combines Pluronic® F127 micelles with polyplexes spontaneously formed by electrostatic interaction between anionic siRNA and cationic polyethylenimine (PEI) 10K, was designed (PM)...
November 2018: Drug Delivery
https://www.readbyqxmd.com/read/29667006/establishment-and-characterization-of-a-c57bl-6-mouse-model-of-bone-metastasis-of-breast-cancer
#2
Toru Hiraga, Tadashi Ninomiya
Bone is one of the most common sites of metastasis in patients with advanced breast cancer; however, the mechanisms of bone metastasis remain to be fully elucidated. Animal models are essential research tools for investigating the mechanisms of diseases and drug actions. To date, there have only been a few reports in which C57BL/6 mice were used for the study of bone metastases of breast cancer. In the current study, we found that intracardiac inoculation of C57BL/6 mouse-derived parental E0771 breast cancer cells (E0771/Pa) frequently lead to bone metastases in C57BL/6 mice within 2 weeks...
April 17, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29666928/implications-of-esr1-mutations-in-hormone-receptor-positive-breast-cancer
#3
REVIEW
Tomás Reinert, Rodrigo Gonçalves, José Bines
Endocrine treatment resistance eventually develops during adjuvant and even more often during hormonal treatment for advanced breast cancer (ABC). An ESR1 gene mutation, which encodes for the estrogen receptor (ER) protein, is one of the potential mechanisms of therapy resistance. The ESR1 mutations result in conformational changes in the ER leading to subsequent estrogen-independent transcriptional activity. These mutations are found at a lower level in early stage when compared to metastatic BC, more often through selective pressure after aromatase inhibitor (AI) treatment...
April 17, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29666189/single-cell-rna-seq-reveals-cell-heterogeneity-and-hierarchy-within-mouse-mammary-epithelia
#4
Heng Sun, Zhengqiang Miao, Xin Zhang, Un In Chan, Sek Man Su, Sen Guo, Chris Koon Ho Wong, Xiaoling Xu, Chu-Xia Deng
The mammary gland is very intricately and well organized into distinct tissues, including epithelia, endothelia, adipocytes, and stromal and immune cells. Many mammary gland diseases, such as breast cancer arise from abnormalities in the mammary epithelium, which is mainly composed of two distinct lineages, the basal and luminal cells. Because of the limitation of traditional transcriptome analysis of bulk mammary cells, the hierarchy and heterogeneity of mammary cells within these two lineages remain unclear...
April 17, 2018: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29665663/-analysis-of-neoadjuvant-docetaxel-carboplatin-and-trastuzumab-tch-in-her-2-positive-breast-cancer
#5
L Xu, J M Ye, S N Zhu, J Y Zhao, L Xin, Y J Cheng, Q Liu, H Zhang, S Zhang, X N Duan, Y H Liu
Objective: To analyze docetaxel (T) and carboplatin (C) combined with trastuzumab (H) -TCH regimen as neoadjuvant systemic therapy in early breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positive. Methods: From January 2008 to December 2014, the data of patients diagnosed as early breast cancer in Breast Disease Center of Peking University First Hospital were retrospective reviewed. The data of patients with HER-2 positive conducted TCH neoadjuvant therapy and surgery, and with the complete clinicopathological information were analyzed...
March 27, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29664714/randomized-phase-ii-trial-of-fulvestrant-plus-everolimus-or-placebo-in-postmenopausal-women-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer-resistant-to-aromatase-inhibitor-therapy-results-of-pre0102
#6
Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, Phillip J Stella, Brian Burnette, Melinda Telli, Della F Makower, Puneet Cheema, Cristina I Truica, Antonio C Wolff, Gamini S Soori, Barbara Haley, Timothy R Wassenaar, Lori J Goldstein, Kathy D Miller, Joseph A Sparano
Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that everolimus plus the selective ER downregulator fulvestrant would be more efficacious than fulvestrant alone in ER-positive metastatic breast cancer resistant to aromatase inhibitor (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131 postmenopausal women with ER-positive, human epidermal growth factor receptor 2-negative, AI-resistant metastatic breast cancer randomly assigned to fulvestrant (500 mg days 1 and 15 of cycle 1, then day 1 of cycles 2 and beyond) plus everolimus or placebo...
April 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29664501/good-health-indicators-in-children-with-down-syndrome-high-frequency-of-exclusive-breastfeeding-at-6-months
#7
Lorena Génova, Jaime Cerda, Catalina Correa, Natalia Vergara, Macarena Lizama
AIM: To describe the frequency of exclusive breastfeeding at 6 months in binomial of mother and in fants with Down Syndrome (DS) attending at the Health net UC CHRISTUS (PSSPSD-UC), and iden tify the main factors associated with exclusive breastfeeding cessation. PATIENTS AND METHODS: Prevalence study of exclusively breastfeeding at 6 months of age that includes mother-child binomial of Chilean infants with (DS) aged 6-24 months, who attend the PSSPSD-UC. An on-line questionnaire was conducted, which included demographic data, child's background and experience in breastfee ding...
February 2018: Revista Chilena de Pediatría
https://www.readbyqxmd.com/read/29663479/quantifying-rater-variation-for-ordinal-data-using-a-rating-scale-model
#8
Shiqi Zhang, Jørgen Holm Petersen
We present a model-based approach to the analysis of agreement between different raters in a situation where all raters have supplied ordinal ratings of the same cases in a sample. It is assumed that no "gold standard" is available. The model is an ordinal regression model with random effects-a so-called rating scale model. The model includes case-specific parameters that allow each case his or hers own level (disease severity). It also allows raters to have different propensities to score a given set of individuals more or less positively-the rater level...
April 16, 2018: Statistics in Medicine
https://www.readbyqxmd.com/read/29662653/plasma-thymidine-kinase-1-activity-predicts-outcome-in-patients-with-hormone-receptor-positive-and-her2-negative-metastatic-breast-cancer-treated-with-endocrine-therapy
#9
Martina Bonechi, Francesca Galardi, Chiara Biagioni, Francesca De Luca, Mattias Bergqvist, Magnus Neumüller, Cristina Guarducci, Giulia Boccalini, Stefano Gabellini, Ilenia Migliaccio, Angelo Di Leo, Marta Pestrin, Luca Malorni
The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine therapy (ET). We used the DiviTum™ assay to analyze TK1 activity in cell lysates of three HR+/HER2neg BC cell lines and in plasma of 31 HR+/HER2neg MBC patients receiving ET. Blood samples were collected at treatment initiation, after one month and at disease progression...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662632/regulation-of-breast-cancer-induced-bone-disease-by-cancer-specific-ikk%C3%AE
#10
Silvia Marino, Ryan T Bishop, Mattia Capulli, Antonia Sophocleous, John G Logan, Patrick Mollat, Barbara Mognetti, Luca Ventura, Andrew H Sims, Nadia Rucci, Stuart H Ralston, Aymen I Idris
NFκB is implicated in breast cancer bone metastasis and skeletal remodelling. However, the role of IKKβ, a key component of the canonical NFκB pathway, in the regulation of breast cancer osteolytic metastasis has not been investigated. Here, we describe the cancer-specific contribution of IKKβ to bone metastasis, skeletal tumour growth and osteolysis associated with breast cancer. IKKβ is highly expressed in invasive breast tumours and its level of expression was higher in patients with bone metastasis...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662623/cancer-reversion-with-oocyte-extracts-is-mediated-by-cell-cycle-arrest-and-induction-of-tumour-dormancy
#11
Norazalina Saad, Ramiro Alberio, Andrew D Johnson, Richard D Emes, Tom C Giles, Philip Clarke, Anna M Grabowska, Cinzia Allegrucci
Inducing stable control of tumour growth by tumour reversion is an alternative approach to cancer treatment when eradication of the disease cannot be achieved. The process requires re-establishment of normal control mechanisms that are lost in cancer cells so that abnormal proliferation can be halted. Embryonic environments can reset cellular programmes and we previously showed that axolotl oocyte extracts can reprogram breast cancer cells and reverse their tumorigenicity. In this study, we analysed the gene expression profiles of oocyte extract-treated tumour xenografts to show that tumour reprogramming involves cell cycle arrest and acquisition of a quiescent state...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662529/neoadjuvant-chemotherapy-in-locally-advanced-duodenal-adenocarcinoma
#12
Carlos Velandia, Rafael Delgado Morales, Carlos Coello, Armando Gil Mendoza, Gabriel Pérez, Emperatriz Aguero
Duodenal adenocarcinoma (ADC) represents only 0.3% of gastrointestinal neoplasms. With the frequency being higher between the ages of 40 and 60, it is predominantly located in the second part of the duodenum and around the periampullary region. Symptoms are nonspecific, so the majority of patients present with advanced disease. Neoadjuvant chemotherapy is a therapeutic option that has not been well studied. The global literature includes only isolated reports on this subject. This is why we are presenting the following case: a 60-year-old female patient with a locally advanced, inoperable duodenal ADC received neoadjuvant chemotherapy...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29662198/the-mir-106b-25-cluster-mediates-breast-tumor-initiation-through-activation-of-notch1-via-direct-repression-of-nedd4l
#13
A L Guarnieri, C G Towers, D J Drasin, M U J Oliphant, Z Andrysik, T J Hotz, R L Vartuli, E S Linklater, A Pandey, S Khanal, J M Espinosa, H L Ford
Tumor-initiating cells (TIC) represent a subset of tumor cells with increased self-renewal capability. TICs display resistance to frontline cancer treatment and retain the ability to repopulate a tumor after therapy, leading to cancer relapse. NOTCH signaling has been identified as an important driver of the TIC population, yet mechanisms governing regulation of this pathway in cancer remain to be fully elucidated. Here we identify a novel mechanism of NOTCH regulation and TIC induction in breast cancer via the miR-106b-25 miRNA cluster...
April 17, 2018: Oncogene
https://www.readbyqxmd.com/read/29662164/transcription-factors-operate-across-disease-loci-with-ebna2-implicated-in-autoimmunity
#14
John B Harley, Xiaoting Chen, Mario Pujato, Daniel Miller, Avery Maddox, Carmy Forney, Albert F Magnusen, Arthur Lynch, Kashish Chetal, Masashi Yukawa, Artem Barski, Nathan Salomonis, Kenneth M Kaufman, Leah C Kottyan, Matthew T Weirauch
Explaining the genetics of many diseases is challenging because most associations localize to incompletely characterized regulatory regions. Using new computational methods, we show that transcription factors (TFs) occupy multiple loci associated with individual complex genetic disorders. Application to 213 phenotypes and 1,544 TF binding datasets identified 2,264 relationships between hundreds of TFs and 94 phenotypes, including androgen receptor in prostate cancer and GATA3 in breast cancer. Strikingly, nearly half of systemic lupus erythematosus risk loci are occupied by the Epstein-Barr virus EBNA2 protein and many coclustering human TFs, showing gene-environment interaction...
April 16, 2018: Nature Genetics
https://www.readbyqxmd.com/read/29661777/interferon-stimulated-genes-are-involved-in-cross-resistance-to-radiotherapy-in-tamoxifen-resistant-breast-cancer
#15
Annemarie E M Post, Marcel Smid, Anika Nagelkerke, John W M Martens, Johan Bussink, Fred Cjg Sweep, Paul N Span
PURPOSE: Treatment resistance is a main cause of adverse disease outcome in breast cancer patients. Here we aimed to investigate common features in tamoxifen-resistant and radioresistant breast cancer, since tamoxifen-resistant breast cancer cells are cross-resistant to irradiation in vitro. EXPERIMENTAL DESIGN: RNA sequencing of tamoxifen-resistant and radioresistant breast cancer cells was performed and validated by quantitative PCR. Pathways were further investigated in vitro and in breast cancer patient cohorts to establish their relation with treatment resistance...
April 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29661250/isocitrate-dehydrogenase-1-snail-axis-dysfunction-significantly-correlates-with-breast-cancer-prognosis-and-regulates-cell-invasion-ability
#16
Wen-Shan Liu, Shih-Hsuan Chan, Hong-Tai Chang, Guan-Cheng Li, Ya-Ting Tu, Hui-Hwa Tseng, Ting-Ying Fu, Hui-Yu Chang, Huei-Han Liou, Luo-Ping Ger, Kuo-Wang Tsai
BACKGROUND: The isocitrate dehydrogenase (IDH) gene family expresses key functional metabolic enzymes in the Krebs cycle and mediates the epigenetic reprogramming, which serves as an important biomarker of breast cancer. However, the expression levels of the IDH protein and their biological function in human breast cancer remain largely unknown. METHODS: In this study, the clinical impact of IDH1 expression on the progression and prognosis of breast cancer was evaluated using immunohistochemistry assay (IHC) of the corresponding tumor-adjacent normal, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) tissues from 309 patients with breast ductal carcinoma...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29660894/overall-survival-of-elderly-patients-with-breast-cancer-is-not-related-to-breast-cancer-specific-survival-a-single-institution-experience-in-japan
#17
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
BACKGROUND: As the aging population grows, the number of elderly breast cancer patients has rapidly increased especially in Japan; a suitable treatment for elderly patients, considering chronic comorbidities and treatment tolerance, is urgently needed. METHODS: In this retrospective study, 286 elderly breast cancer patients were investigated. Tumor characteristics and survival outcome were compared between 70-79-year-old and ≥ 80-year-old groups. Disease-free survival, overall survival, and breast cancer-specific survival were compared, and the effect of variables was analyzed statistically...
April 5, 2018: Breast Disease
https://www.readbyqxmd.com/read/29660596/time-trends-of-overall-survival-among-metastatic-breast-cancer-patients-in-the-real-life-esme-cohort
#18
Elisa Gobbini, Monia Ezzalfani, Véronique Dieras, Thomas Bachelot, Etienne Brain, Marc Debled, William Jacot, Marie Ange Mouret-Reynier, Anthony Goncalves, Florence Dalenc, Anne Patsouris, Jean Marc Ferrero, Christelle Levy, Veronique Lorgis, Laurence Vanlemmens, Claudia Lefeuvre-Plesse, Simone Mathoulin-Pelissier, Thierry Petit, Lionel Uwer, Christelle Jouannaud, Marianne Leheurteur, Magali Lacroix-Triki, Audrey Lardy Cleaud, Mathieu Robain, Coralie Courtinard, Christian Cailliot, David Perol, Suzette Delaloge
AIM: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort. METHODS: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014)...
April 13, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29659933/circulating-tumor-cells-in-breast-cancer-patients-treated-by-neoadjuvant-chemotherapy-a-meta-analysis
#19
François-Clément Bidard, Stefan Michiels, Sabine Riethdorf, Volkmar Mueller, Laura J Esserman, Anthony Lucci, Bjørn Naume, Jun Horiguchi, Rafael Gisbert-Criado, Stefan Sleijfer, Masakazu Toi, Jose A Garcia-Saenz, Andreas Hartkopf, Daniele Generali, Françoise Rothé, Jeffrey Smerage, Laura Muinelo-Romay, Justin Stebbing, Patrice Viens, Mark Jesus M Magbanua, Carolyn S Hall, Olav Engebraaten, Daisuke Takata, José Vidal-Martínez, Wendy Onstenk, Noriyoshi Fujisawa, Eduardo Diaz-Rubio, Florin-Andrei Taran, Maria Rosa Cappelletti, Michail Ignatiadis, Charlotte Proudhon, Denise M Wolf, Jessica B Bauldry, Elin Borgen, Rin Nagaoka, Vicente Carañana, Jaco Kraan, Marisa Maestro, Sara Yvonne Brucker, Karsten Weber, Fabien Reyal, Dominic Amara, Mandar G Karhade, Randi R Mathiesen, Hideaki Tokiniwa, Antonio Llombart-Cussac, Alessandra Meddis, Paul Blanche, Koenraad d'Hollander, Klaus Pantel
Background: We conducted a meta-analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (CTC) detection as a prognostic marker. Methods: We collected individual patient data from 21 studies in which CTC detection by CellSearch was performed in early breast cancer patients treated with NCT. The primary end point was overall survival, analyzed according to CTC detection, using Cox regression models stratified by study...
April 12, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29659715/the-cost-effectiveness-of-follow-up-strategies-after-cancer-treatment-a-systematic-literature-review
#20
M Barbieri, G Richardson, S Paisley
Introduction: The cost of treatment and follow-up of cancer patients in the UK is substantial. In a budget-constrained system such as the NHS, it is necessary to consider the cost-effectiveness of the range of management strategies at different points on cancer patients' care pathways to ensure that they provide adequate value for money. Sources of data: We conducted a systematic literature review to explore the cost-effectiveness of follow-up strategies of patients previously treated for cancer with the aim of informing UK policy...
April 12, 2018: British Medical Bulletin
keyword
keyword
51147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"